The announcement of new data from the ongoing Phase 1 clinical trial of CAN-3110 in recurrent high-grade glioma is a positive development for Candel Therapeutics. This news may lead to increased investor interest and confidence in the company's potential, resulting in a positive short-term impact on the stock price.